# Protagonist Therapeutics, Inc.

Type: Company (PTGX)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/protagonist-therapeutics-inc
Canonical HTML page: https://getbiobrief.com/entity/protagonist-therapeutics-inc

## Recent coverage (1 stories)

### Protagonist's $300M Buyback: Rare Cash Return After 2 FDA Wins
2026-09-08 22:27:59 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist's board authorized a $300 million repurchase, backed by $849.5 million in cash and royalty streams from two FDA-approved drugs. For biotech observers, the move marks a shift from cash burn to capital return as partnered products generate milestone and royalty income.
Full story: https://getbiobrief.com/story/protagonist-300m-buyback-biotech-capital-pivot

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.